Bourne Lent Asset Management Inc. held its stake in shares of Eli Lilly and Co. (NYSE:LLY) during the second quarter, Holdings Channel reports. The fund owned 4,614 shares of the company’s stock at the end of the second quarter. Bourne Lent Asset Management Inc.’s holdings in Eli Lilly and were worth $363,000 at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of LLY. RNC Capital Management LLC raised its stake in shares of Eli Lilly and by 42.4% in the second quarter. RNC Capital Management LLC now owns 410,784 shares of the company’s stock worth $32,349,000 after buying an additional 122,237 shares in the last quarter. Private Capital Advisors Inc. acquired a new position in shares of Eli Lilly and during the second quarter worth approximately $28,535,000. AMP Capital Investors Ltd raised its position in shares of Eli Lilly and by 6.9% in the first quarter. AMP Capital Investors Ltd now owns 512,346 shares of the company’s stock worth $36,776,000 after buying an additional 32,848 shares during the period. Country Trust Bank raised its position in shares of Eli Lilly and by 0.4% in the second quarter. Country Trust Bank now owns 252,356 shares of the company’s stock worth $19,873,000 after buying an additional 909 shares during the period. Finally, Sector Gamma AS raised its position in shares of Eli Lilly and by 89.8% in the first quarter. Sector Gamma AS now owns 771,390 shares of the company’s stock worth $55,548,000 after buying an additional 365,000 shares during the period. Hedge funds and other institutional investors own 74.96% of the company’s stock.
Shares of Eli Lilly and Co. (NYSE:LLY) traded up 1.71% on Tuesday, hitting $80.88. 6,888,929 shares of the stock were exchanged. Eli Lilly and Co. has a 12 month low of $67.88 and a 12 month high of $88.48. The company has a market cap of $85.55 billion, a PE ratio of 34.86 and a beta of 0.20. The company has a 50-day moving average price of $79.29 and a 200 day moving average price of $77.02.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.86. The company had revenue of $5.40 billion for the quarter, compared to the consensus estimate of $5.14 billion. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The firm’s revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.90 earnings per share. Equities analysts forecast that Eli Lilly and Co. will post $3.59 EPS for the current fiscal year.
A number of brokerages have recently commented on LLY. JPMorgan Chase & Co. upgraded shares of Eli Lilly and from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $92.00 to $95.00 in a report on Thursday, September 8th. Leerink Swann reiterated an “outperform” rating and set a $105.00 price target on shares of Eli Lilly and in a report on Saturday, August 13th. Jefferies Group reiterated a “buy” rating and set a $105.00 price target on shares of Eli Lilly and in a report on Wednesday, September 14th. BMO Capital Markets reiterated a “buy” rating and set a $94.00 price target on shares of Eli Lilly and in a report on Wednesday, July 27th. Finally, SunTrust Banks Inc. reiterated a “buy” rating on shares of Eli Lilly and in a report on Wednesday, June 15th. Two research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. Eli Lilly and presently has an average rating of “Buy” and a consensus target price of $97.16.
In other news, Director Jackson P. Tai purchased 2,560 shares of the stock in a transaction on Friday, August 12th. The shares were acquired at an average price of $80.42 per share, with a total value of $205,875.20. Following the completion of the acquisition, the director now directly owns 42,110 shares of the company’s stock, valued at $3,386,486.20. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of Eli Lilly and stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $78.46, for a total transaction of $16,868,900.00. Following the transaction, the insider now directly owns 126,808,704 shares in the company, valued at approximately $9,949,410,915.84. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co. (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.